{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:13:18Z","timestamp":1648599198280},"reference-count":1,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1097\/md.0000000000006958","type":"journal-article","created":{"date-parts":[[2017,5,16]],"date-time":"2017-05-16T14:40:18Z","timestamp":1494945618000},"page":"e6958","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs"],"prefix":"10.1097","volume":"96","member":"276","reference":[{"key":"R1-37-20210309","doi-asserted-by":"crossref","first-page":"e5321","DOI":"10.1097\/MD.0000000000005321","article-title":"Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs","volume":"96","author":"Lee","year":"2017","journal-title":"Medicine"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000006958","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:50:24Z","timestamp":1620960624000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201705190-00037"}},"subtitle":["Erratum"],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":1,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000006958","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}